PMDA — authorised 29 June 2020
- Marketing authorisation holder: Novartis Pharma K.K.
- Status: approved
🇯🇵 Elocon in Japan
PMDA authorised Elocon on 29 June 2020
Marketing authorisation
Elocon in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Japan
Frequently asked questions
Is Elocon approved in Japan?
Yes. PMDA authorised it on 29 June 2020.
Who is the marketing authorisation holder for Elocon in Japan?
Novartis Pharma K.K. holds the Japanese marketing authorisation.